Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 14;9(10):e20903.
doi: 10.1016/j.heliyon.2023.e20903. eCollection 2023 Oct.

Association between depressive and anxious symptoms with cognitive function and quality of life in drug-resistant epilepsy

E Monteagudo-Gimeno  1   2 , R Sánchez-González  3   4 , J Raduà-Castaño  5   6   7   8   9 , L Fortea-González  5   7   10 , T Boget-Llucià  5   10   11 , M Carreño-Martínez  5   10   11 , A Donaire-Pedraza  5   10   11 , N Bargalló-Alabart  5   11 , X Setoain-Perego  5   10   11   12 , J Rumià-Arboix  10   11 , A Bulbena-Vilarrasa  1   3 , L Pintor-Pérez  5   10   13
Affiliations

Association between depressive and anxious symptoms with cognitive function and quality of life in drug-resistant epilepsy

E Monteagudo-Gimeno et al. Heliyon. .

Erratum in

Abstract

•Depressive/anxious disorders and cognitive impairment are frequent comorbidities in epilepsy and have a more deleterious effect in DRE.•Studies concerning the relationship between anxiety and depression and cognitive performance in DRE are scarce.•Higher scores in HADS are associated with lower QOLIE-31 scores and might be considered as predictors of QOL in DRE.•A relationship between anxious and depressive symptoms -measured with HADS and SCL-90R- and cognition might not exist.•There remains an unexplored study area regarding this relationship which requires more attention to improve the assessment of DRE.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Association between quality of life measured by QOLIE-31 and presence of depressive symptoms assessed by HADS.
Fig. 2
Fig. 2
Association between quality of life measured by QOLIE-31 and presence of anxious symptoms assessed by HADS.
See this image and copyright information in PMC

References

    1. Thijs R.D., Surges R., O'Brien T.J., Sander J.W. Epilepsy in adults. Lancet (London, England) 2019;393:689–701. doi: 10.1016/S0140-6736(18)32596-0. - DOI - PubMed
    1. Kalilani L., Sun X., Pelgrims B., Noack-Rink M., Villanueva V. The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsia. 2018;59:2179–2193. doi: 10.1111/epi.14596. - DOI - PubMed
    1. Kwan P., Arzimanoglou A., Berg A.T., Brodie M.J., Allen Hauser W., Mathern G., et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2009;51:1069–1077. doi: 10.1111/j.1528-1167.2009.02397.x. - DOI - PubMed
    1. Laxer K.D., Trinka E., Hirsch L.J., Cendes F., Langfitt J., Delanty N., et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014;37:59–70. doi: 10.1016/j.yebeh.2014.05.031. - DOI - PubMed
    1. Tellez-Zenteno J.F., Patten S.B., Jetté N., Williams J., Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007;48:2336–2344. doi: 10.1111/j.1528-1167.2007.01222.x. - DOI - PubMed

LinkOut - more resources